Pharmather Holdings Ltd · CSE:PHRM
Pharmather — Investor Presentation (October 2026)
25 slides from Pharmather's investor presentation, October 2026
Slide 1: Pharmaceutical 3D Printing of Personalized Medicine
Pharmaceutical 3D Printing of Personalized Medicine. pharmather.com Corporate Presentation · October 2026 CSE: PHRM | OTCQB: PHRRF
Slide 2: Forward-Looking Statements
IM POR TA NT NOT ICE Forward-Looking Statements This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-look
Slide 3: Pharmaceutical 3D printing for personalized medicine
WH O WE AR E Pharmaceutical 3D printing for personalized medicine. P L AT F O R M M3DICINES Validated formulations · GMP-ready CraftMake printing · Any dose, release or combination Any dose. P I P EL I N E Any release. Proprietary products Any combination — Peptides (colon-targeted + longevity) · Ra
Slide 4: Medicine is made for everyone. We make it for one.
OUR M ISSION Medicine is made for everyone. We make it for one. CSE: PHRM | OTCQB: PHRRF
Slide 5: Mass manufacturing leaves many patients poorly served
WH Y 3D -PR IN TED M ED ICINE S MA TT ER Mass manufacturing leaves many patients poorly served. Conventional manufacturing pays off only at hundreds of thousands to millions of identical units. Personalized doses Often only injections or a few fixed strengths Children and rare diseases Split tablets
Slide 6: The exact dose, for the specific patient, on demand — economically
WH Y PHAR M AC EUT ICAL 3 D PR IN TIN G The exact dose, for the specific patient, on demand — economically. Five things mass production can’t do economically — and why each one creates value. Batch size Dose Pill design Process Where it’s made 10 mg 20 mg 40 mg TOD AY Heat Pressure UV Overseas Patie
Slide 7: M3DICINES 3D-printed medicines
OUR PLA TFORM M3DICINES 3D-printed medicines. Precise, room-temperature (no heat, no UV) printing of customized doses on GMP-ready CraftMake systems. CR A FTM AK E 3 D P RI NT E R F LE X I B L E D O S A G E F O R M S Beads & mini-tablets Dual-print tablets Gummies & chewables Multi-layered tablets L
Slide 8: Exclusive North American distributor of CraftMake pharmaceutical 3D printing
COM M ER CIAL F OUN DA TION Exclusive North American distributor of CraftMake pharmaceutical 3D printing. 10,000+ potential M3DICINES Network sites across North America (management estimate). WHA T WE D IS T R IB UT E NE T W OR K P AR T N E R S A ND C US T OM E R S • CraftMake printers: enclosed, GM
Slide 9: Regulation, demand, technology and preparedness are converging
WH Y NOW Regulation, demand, technology and preparedness are converging. US$141B → US$295B US$567B → US$1.2T US$41B → US$59B Peptide therapeutics market, Global personalized-medicine market, Medical countermeasures market, 2025 → 2033 2024 → 2033 2025 → 2030 MEDIC A L REG U LA TIO N IS MO VI NG DEMA
Slide 10: Two pillars. One platform.
BUSIN ESS M ODEL Two pillars. One platform. WE OWN the products, formulations and network. WE OPEN the platform to partners. P I L L A R 1 · P RO DU C T P I P E L IN E P I L L A R 2 · P A RT N E RI NG & T EC HN O L O GY Personalized 503A products, including peptides and longevity stacks Network plac
Slide 11: Six pipeline areas. One printing platform.
P R O D U C T P I P E L IN E Six pipeline areas. One printing platform. Where a precise dose, a combination or a small batch makes a medicine possible. P R O G RA M PA T HW AY S TATUS N E X T M I L ES T O N E Colon-targeted peptide (BPC-157) 503A, once FDA rulemaking allows AW AI T I N G F DA FDA ru
Slide 12: GAMT deficiency: a treatable disease with no FDA-approved treatment
F D A D E S I G N A T I O N A P P L I C A T I O N S S U B M IT T E D · O C T O B E R 2 0 2 6 GAMT deficiency: a treatable disease with no FDA-approved treatment. Orphan Drug and Rare Pediatric Disease Designation applications filed for 3D-printed creatine monohydrate. T H E D I SE A SE TOD AY ’S TRE
Slide 13: Dose precision is the product
F D A P RO D U CT S PO T L IGH T · G AM T D E FICIE NCY Dose precision is the product. Children with GAMT deficiency take creatine powder mixed by hand, several times a day, for life. L E A D F D A - T R AC K PR OG R A M · 5 0 5 ( b ) (1 ) · OD D + R P D S U B M I T T E D TOD AY High-dose creatine p
Slide 14: Approval can earn a priority review voucher
THE PRV OPPORTU N ITY Approval can earn a priority review voucher; recent sales: US$150–200M. WH A T R A R E P E D I A T R I C VO U C H E R S H AV E S OL D FO R ( U S $ M I L L I ON S , R E P OR T E D ) H OW T HE I N CE N T I VE S WOR K $350 Orphan Drug Designation 1 7 years of market exclusivity, N
Slide 15: Three underserved markets where small-batch production is an advantage
PIPE LINE EX PAN SION Three underserved markets where small-batch production is an advantage. Each is too small for a production line, and exactly right for pharmaceutical 3D printing. E V A LU AT I N G P LAN N E D E V A LU AT I N G Rare diseases Psychedelic medicines Discontinued & short-supply Too
Slide 16: A national medicines network
M 3D ICINES N AT I ON A L NE TWO R K P R O G RA M A national medicines network. Qualified sites make medicines close to the patients who need them. Remote areas 1 · Validate Provincial / PharmaTher and partners validate M3DICINES formulations and recipes regional nodes PharmaTher control site 2 · Qu
Slide 17: Built on the network, not on selling as many printers as possible
M 3D ICINES N ETW O RK · B US IN ES S M O D EL Built on the network, not on selling as many printers as possible. 1 · P LA C E + 1 NO DE 2 · L IC ENSE 3 · SE LL Network placements M3DICINES product offerings White-label programs CraftMake systems placed as network Validated formulations for 503A com
Slide 18: Commercial work in peacetime. Countermeasures in an emergency.
N AT I ON A L EM ER G EN C Y P R EP A R ED N ES S N O D E N ETW O R K · P L A N NED Commercial work in peacetime. Countermeasures in an emergency. Stockpile the inputs, not the pills. T O D A Y' S S T O CK P I L E S IN P EA C ETI ME IN A N EME RGENC Y Finished medicines in a few standard Nodes do co
Slide 19: An asset-light model with three partners, already in place
EX ECU TIO N FO O T PRIN T An asset-light model with three partners, already in place. H A R D WA R E DISP ENSI NG A ND R&D M A N U F A CT U R I N G Exclusive North American distributor Center of Excellence GMP contract manufacturer CraftMake systems, software, materials and service. PD Labs: a U.S.
Slide 20: Non-dilutive upside outside the 3D printing core
STRA TEGIC A SSET S Non-dilutive upside outside the 3D printing core. Ketamine ANDA payments expected to begin Q1 2027. Other assets available to license, sell, partner or spin out. Ketamine ANDA KetaVault Ketamine patch KetaMist® Sairiyo Therapeutics FDA-approved ketamine CMC package, INDs, protoco
Slide 21: How our revenue stacks — each layer builds on the last
POTE NT IAL R EV EN UE M ODE L How our revenue stacks — each layer builds on the last. Revenue layers are designed to build on each other — all from the same M3DICINES platform, formulations and data. Approvals add step-change value Priority review voucher sale (recent: US$150–200M) A rare pediatric
Slide 22: Prove. Build. Lead.
M ILESTON ES Prove. Build. Lead. P RO V E 0–1 2 M ON THS BU I L D 1 2–3 6 M ON THS L EA D BE YO ND First 503A launches, including the NAD+ and NMN New programs: ultra-rare, psychedelic, Products longevity stack, colon-targeted peptides Q4 2026 discontinued and short-supply Expanded product and syste
Slide 23: Our Team
OUR T EAM Leadership across drug development, FDA approvals, commercialization, manufacturing and capital markets. MANAGEMENT & BOA RD CS Fabio Chianelli Carmelo Marrelli Dr. Beverly J. Incledon Carlo Sansalone Founder, Chairman & CEO Chief Financial Officer Director Director 25+ years in specialty
Slide 24: Capital structure
COM PA NY Capital structure As at September 30, 2026 91,019,065 1,500,000 ~19% Issued and outstanding common shares Stock options outstanding Insider ownership PHRM (CSE) PHRRF (OTCQB) COMPANY F ACTS Transfer agent Auditor Fiscal year-end Filings Marrelli Trust Company Limited Truster Zweig Raithath
Slide 25: Thank You
Thank You [email protected] · 1-888-846-3171 PharmaTher Holdings Ltd. pharmather.com CSE: PHRM | OTCQB: PHRRF
PharmaTher Holdings — Investor Presentation (October 2026) on 6ix